This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea

This study has been completed.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Sanjay R Patel, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01629862
First received: May 8, 2012
Last updated: May 26, 2017
Last verified: May 2017
May 8, 2012
May 26, 2017
April 2012
February 2017   (Final data collection date for primary outcome measure)
Change in brachial artery flow-mediated dilation. [ Time Frame: Between baseline & 3-month follow-up. ]
Same as current
Complete list of historical versions of study NCT01629862 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea
Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea.

The investigators will examine the possible synergistic effects of obstructive sleep apnea (OSA) and type II diabetes mellitus (DM) on vascular functioning by performing a two-part investigation:

  • A cross-sectional study comparing subjects with OSA+DM, OSA only, DM only, and healthy controls.
  • A three-month randomized placebo-controlled trial of continuous positive airway pressure (CPAP) in subjects with OSA+DM.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
  • Sleep Apnea, Obstructive
  • Diabetes Mellitus
  • Device: Continuous positive airway pressure
    CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
  • Device: Sham continuous positive airway pressure
    CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
  • Active Comparator: Active CPAP
    Therapeutic continuous positive airway pressure (CPAP).
    Intervention: Device: Continuous positive airway pressure
  • Placebo Comparator: Sham CPAP
    Sham (non-therapeutic) continuous positive airway pressure.
    Intervention: Device: Sham continuous positive airway pressure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
53
February 2017
February 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • OSA subjects: apnea-hypopnea index >=10 and <100
  • DM subjects: clinical diagnosis of DM and glycated hemoglobin < 8.0%

Exclusion Criteria:

  • Hematocrit < 32
  • Pregnancy
  • Infectious/collagen vascular/hepatic or renal/cardiopulmonary disease
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01629862
8354706
Yes
Not Provided
Not Provided
Not Provided
Sanjay R Patel, University of Pittsburgh
University of Pittsburgh
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • National Institutes of Health (NIH)
Principal Investigator: Aristidis Veves, MD Beth Israel Deaconess Medical Center
Principal Investigator: Sanjay R Patel, MD University of Pittsburgh
University of Pittsburgh
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP